Bimekizumab - UCB Pharma

Drug Profile

Bimekizumab - UCB Pharma

Alternative Names: Anti-IL-17-mAb-UCB; Anti-IL-17-monoclonal-antibody-UCB; Anti-interleukin-17-monoclonal-antibody-UCB; CDP-4940; UCB-4940

Latest Information Update: 16 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator UCB
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Antiulcers; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action IL17A protein inhibitors; IL17F protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Plaque psoriasis; Psoriatic arthritis
  • Phase II Ankylosing spondylitis; Hidradenitis suppurativa; Rheumatoid arthritis; Ulcerative colitis
  • No development reported Psoriasis

Most Recent Events

  • 26 Jul 2018 UCB Pharma plans phase III studies in Psoriatic arthritis and Ankylosing spondylitis by end-2018
  • 25 Jul 2018 UCB Biopharma plans the BE BRIGHT phase III trial for Plaque psoriasis in August 2018 , (NCT03598790)
  • 01 Jul 2018 UCB Biopharma completes a phase II trial in Psoriatic arthritis (Adjunctive treatment) in Czech Republic, Germany, Hungary, Poland, Russia, USA (SC) (NCT02969525)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top